GAVRETO (pralsetinib)
TherapyRigel Pharmaceuticals
GAVRETO (pralsetinib) from Rigel Pharmaceuticals is a targeted inhibitor for tumors driven by RET alterations.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and GAVRETO. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where GAVRETO is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung | RET
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for GAVRETO.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering GAVRETO for eligible patients.
Test
Oncomine Dx Target Test
Life Technologies Corporation (ThermoFisher Scientific)
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →